Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2012

Filed with the SEC on Nov 2, 2012 and accepted by EDGAR at Nov 2, 2012, 08:14 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2012-07-01 to 2012-09-30$3.1mus-gaap:Revenues
Revenue9 months2012-01-01 to 2012-09-30$7.6mus-gaap:Revenues
Research and development3 months2012-07-01 to 2012-09-30$11.8mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2012-01-01 to 2012-09-30$33.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2012-07-01 to 2012-09-30−$14.8mus-gaap:OperatingIncomeLoss
Operating income9 months2012-01-01 to 2012-09-30−$41.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2012-07-01 to 2012-09-30$381.0kus-gaap:InterestExpense
Interest expense9 months2012-01-01 to 2012-09-30$1.2mus-gaap:InterestExpense
Net income3 months2012-07-01 to 2012-09-30−$15.0mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income9 months2012-01-01 to 2012-09-30−$42.3mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2012-07-01 to 2012-09-30−$0.25us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2012-01-01 to 2012-09-30−$0.75us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2012-01-01 to 2012-09-30−$36.5mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure9 months2012-01-01 to 2012-09-30$193.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2012-09-30$23.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-09-30$78.8mus-gaap:AssetsCurrent
Total assetsAt period end2012-09-30$119.8mus-gaap:Assets
Current liabilitiesAt period end2012-09-30$15.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-09-30$28.8mus-gaap:Liabilities
Shareholders' equityAt period end2012-09-30$91.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-12-073441. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.